One recent study of reports from the FDAs Adverse Event Reporting System database found that less than 5 percent of complaints about GLP-1s were related to psychiatric symptoms, but GLP-1s were more likely than other medications to be linked to nervousness, stress, eating disorders, fear of injection, insomnia, binge eating, fear of eating, and self-induced vomiting
RELATED: Ozempic for weight loss Key differences between compounded semaglutide and FDA-approved brands Wegovy and Ozempic contain the same active ingredient, semaglutide, a GLP-1 receptor agonist that is FDA approved for weight management and Type 2 diabetes, respectively
At a high volume firm, they'll get to you when they can
NHMRC: National Health and Medical Research Council
The point is this: even if both semaglutide and tirzepatide fail, the medication pipeline contains multiple next-generation options targeting different receptor combinations
doi:10.3389/fphar.2021.627533 Bajramagic S, Sever M, Rasic F, et al